Amended Current Report

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A
(Amendment No. 1)

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2011

SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   001-35006   93-0979187
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
11500 S. Eastern Ave., Ste. 240
Henderson, NV
  89052
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (702) 835-6300
 
N/A
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 5.07  
Submission of Matters to a Vote of Security Holders.
As previously reported, Spectrum Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 13, 2011 at the Company’s California office located at 157 Technology Drive, Irvine, California 92618. At the Annual Meeting, among other matters, the Company’s stockholders indicated that the frequency of the advisory vote on executive compensation should be every year. In light of the results of the stockholder advisory vote on the frequency of the advisory vote on executive compensation, the Company’s Board of Directors has decided to hold the stockholder advisory vote on executive compensation every year. Accordingly, the next stockholder advisory vote on executive compensation will be held at the Company’s 2012 Annual Meeting of Stockholders.

 

 

 

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Spectrum Pharmaceuticals, Inc.
  		 
Date: November 10, 2011  By:   /s/ Brett L. Scott    
    Name:   Brett L. Scott   
    Title:   Senior Vice President and Acting Chief Financial Officer